Not CAR-T / NK / M, new cell therapy technology is coming, the goal is to conquer solid tumors!

Nearly five years after founding CAR-T biotech company Vor Biopharma, renowned oncologist Dr. Siddhartha Mukherjee has made a new move.
January 6, his new company, Myeloid Therapeutics, launched for more than $50 million, with Newpath Partners, 8VC and others to launch clinical trials on T-cell lymphoma, glioblastoma and other solid tumors, as well as further development of myeloid therapy.
the first half of this year, the company's two main projects for glioblastoma and T-cell lymphoma will enter the clinical research phase.
source: Myeloid Therapeutics, based in Massachusetts, USA, is a company that uses myelin cells and reprograms them to treat cancer.
the company combines advanced genetic and cell engineering capabilities with a wealth of biological knowledge to study myelin cells' ability to treat cancer, especially solid tumors and tumors that are not treated well with existing therapies.
company's scientific founders include dr. Ronald Vale, a world-renowned biochemist and cell biologist, and Dr. Siddhartha Mukherjee, an oncologist and Pulitzer Prize winner.
From left to right: Founder Dr. Ronald Vale, Dr. Siddhartha Mukherjee and co-founder Dr. Yuxiao Wang (source: Myeloid Therapeutics official website) Under the leadership of Vale and Dr. Mukherjee, Myeloid developed the ATAK cell platform, which uses myelin-specific identification and devouring of cancer cells to promote anti-tumor immunity and change the tumor microenvironment, ultimately killing cancer cells.
ATAK platform-based products include reprogrammed single-core cell products, new mRNA-based protein and gene delivery products, mixed cell library and chisellular antigens (CAR), and new triple and dual-specific cell bridgers.
Myeloid is currently working on two new types of ATAK therapies: ATAK CAR monocytes and ATAK primed monocytes.
ATAK CAR monocytes are myelin cells that have innate immune bodies that excite CAR to identify and kill cancer cells.
ATAK primed monocytes function like cell vaccines and are programmed to activate T cells to kill cancer cells.
company's products include two leading projects: MT-201 for the treatment of glioblastoma and MT-101 for the treatment of recurring/refractic expression CD5 T-cell lymphoma, and MT-102 for the treatment of HER2-plus tumors and targeting MT-103 for tumors containing TRP2 antigens.
myeloid Therapeutics product pipeline (source: Myeloid Therapeutics website) In addition to treating solid tumors, Myeloid is also working to address another bottleneck in cell therapy: production.
currently approved CAR-T therapy is produced using the patient's own T-cells, making manufacturing expensive and time-consuming.
and Myeloid's candidate therapy takes only a day to complete, and it hopes to offer patients "same-day" treatments.
addition, "off-the-shelf" products may also be an option.
Myeloid co-founder and CEO, said: "Myeloid has built an ATAK platform to overcome many of the limitations of existing cell therapies.
monocytes make up the largest group of immune cells in the tumor micro-environment, and by harnessing forces such as monocytes to penetrate solid tumors and catalytic immune responses, we are working to bring new treatments to patients.
we have also designed and successfully implemented an efficient and flexible manufacturing process that sets a new starting point for cell therapy.
support from a strong investor community has enabled us to further develop the ATAK platform, bring multiple solid tumor projects to clinical level, and advance new conversion projects as we expand our Myeloid pipeline.
Myelin is the body's front-line tool against disease and plays a key role in coordinating adaptive immune responses," said Thomas Cahill, co-founder of Myeloid and managing partner of Newpath Partners.
myelin cells tend to be over-accounted for in solid cancers, and I've been fascinated by their therapeutic potential since I studied them.
other cell therapies that focus on reprogramming the adaptive immune system do improve the prognosis of patients, especially for blood cancer.
to expand that hope, the next logical step is to empower the front-line battle cells of solid tumors.
myelin cells, Myeloid is developing a new treatment that is extremely versatile and effective.
look forward to continuing to support this team through their first wave of clinical trials and future research.
"Medicine Rubik's Cube Source: Pharmaceutical Rubik's Cube Copyright Notice: All text, images and audio and video materials on this website that indicate "Source: Met Medical" or "Source: MedSci Original" are owned by Metz Medicine and are not authorized to be reproduced by any media, website or individual, and are authorized to be reproduced with the words "Source: Mets Medicine".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
at the same time reproduced content does not represent the position of this site.
leave a message here